---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276135"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:22:39.807415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive

## Summary
- Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.
- Workforce reduced by 25%; early discovery and platform research deprioritized.
- Jian Irish promoted to CEO; founder Brian Thomas remains on Board; Willard Dere named Board Chair.
- MGX-001 hemophilia A preclinical data: curative FVIII activity in NHPs at proposed clinical dose averaging 49%.
- Pre-IND meeting expected Q4 2025; IND/CTA submissions targeted for Q4 2026.

## SEC filing metadata
- accession: 0001193125-25-276135
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/0001193125-25-276135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-20251111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276135
- JSON: https://secwatch.observer/filing/0001193125-25-276135.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.